The	O
Effect	O
of	O
Omega	B:C0015689
-	I:C0015689
3	I:C0015689
Supplement	O
on	O
Serum	O
Lipid	I:C0428462
Profile	I:C0428462
in	O
Patients	O
Undergoing	O
Hemodialysis	O
:	O
A	O
Randomized	O
Clinical	I:C0206034
Trial	I:C0206034
.	O

The	O
Effect	O
of	O
Omega	O
-	I:C0015689
3	I:C0015689
Supplement	O
on	O
Serum	B:C0428462
Lipid	I:C0428462
Profile	I:C0428462
in	O
Patients	O
Undergoing	O
Hemodialysis	O
:	O
A	O
Randomized	O
Clinical	I:C0206034
Trial	I:C0206034
.	O

The	O
Effect	O
of	O
Omega	O
-	I:C0015689
3	I:C0015689
Supplement	O
on	O
Serum	O
Lipid	I:C0428462
Profile	I:C0428462
in	O
Patients	O
Undergoing	O
Hemodialysis	B:C0019004
:	O
A	O
Randomized	O
Clinical	I:C0206034
Trial	I:C0206034
.	O

The	O
Effect	O
of	O
Omega	O
-	I:C0015689
3	I:C0015689
Supplement	O
on	O
Serum	O
Lipid	I:C0428462
Profile	I:C0428462
in	O
Patients	O
Undergoing	O
Hemodialysis	O
:	O
A	O
Randomized	B:C0206034
Clinical	I:C0206034
Trial	I:C0206034
.	O

Some	O
recent	O
suggestions	O
could	O
show	O
omega	B:C0015689
-	I:C0015689
3	I:C0015689
condition	O
deficiency	O
following	O
prolonged	O
hemodialysis	O
;	O
however	O
,	O
these	O
claims	O
and	O
speculations	O
have	O
not	O
been	O
well	O
demonstrated	O
with	O
sufficient	O
evidences	O
.	O

Some	O
recent	O
suggestions	O
could	O
show	O
omega	O
-	I:C0015689
3	I:C0015689
condition	O
deficiency	O
following	O
prolonged	O
hemodialysis	B:C0019004
;	O
however	O
,	O
these	O
claims	O
and	O
speculations	O
have	O
not	O
been	O
well	O
demonstrated	O
with	O
sufficient	O
evidences	O
.	O

Hence	O
,	O
we	O
attempted	O
to	O
assess	O
the	O
beneficial	O
effects	O
of	O
omega	B:C0015689
-	I:C0015689
3	I:C0015689
on	O
lipid	O
profile	I:C0428462
in	O
patients	O
with	O
end	O
-	I:C0022661
stage	I:C0022661
renal	I:C0022661
disease	I:C0022661
(	O
end	O
-	I:C0022661
stage	I:C0022661
renal	I:C0022661
disease	I:C0022661
)	O
undergoing	O
hemodialysis	O
.	O

Hence	O
,	O
we	O
attempted	O
to	O
assess	O
the	O
beneficial	O
effects	O
of	O
omega	O
-	I:C0015689
3	I:C0015689
on	O
lipid	B:C0428462
profile	I:C0428462
in	O
patients	O
with	O
end	O
-	I:C0022661
stage	I:C0022661
renal	I:C0022661
disease	I:C0022661
(	O
end	O
-	I:C0022661
stage	I:C0022661
renal	I:C0022661
disease	I:C0022661
)	O
undergoing	O
hemodialysis	O
.	O

Hence	O
,	O
we	O
attempted	O
to	O
assess	O
the	O
beneficial	O
effects	O
of	O
omega	O
-	I:C0015689
3	I:C0015689
on	O
lipid	O
profile	I:C0428462
in	O
patients	O
with	O
end	B:C0022661
-	I:C0022661
stage	I:C0022661
renal	I:C0022661
disease	I:C0022661
(	O
end	O
-	I:C0022661
stage	I:C0022661
renal	I:C0022661
disease	I:C0022661
)	O
undergoing	O
hemodialysis	O
.	O

Hence	O
,	O
we	O
attempted	O
to	O
assess	O
the	O
beneficial	O
effects	O
of	O
omega	O
-	I:C0015689
3	I:C0015689
on	O
lipid	O
profile	I:C0428462
in	O
patients	O
with	O
end	O
-	I:C0022661
stage	I:C0022661
renal	I:C0022661
disease	I:C0022661
(	O
end	B:C0022661
-	I:C0022661
stage	I:C0022661
renal	I:C0022661
disease	I:C0022661
)	O
undergoing	O
hemodialysis	O
.	O

Hence	O
,	O
we	O
attempted	O
to	O
assess	O
the	O
beneficial	O
effects	O
of	O
omega	O
-	I:C0015689
3	I:C0015689
on	O
lipid	O
profile	I:C0428462
in	O
patients	O
with	O
end	O
-	I:C0022661
stage	I:C0022661
renal	I:C0022661
disease	I:C0022661
(	O
end	O
-	I:C0022661
stage	I:C0022661
renal	I:C0022661
disease	I:C0022661
)	O
undergoing	O
hemodialysis	B:C0019004
.	O

One	O
hundred	O
and	O
seventeen	O
end	B:C0022661
-	I:C0022661
stage	I:C0022661
renal	I:C0022661
disease	I:C0022661
patients	O
who	O
were	O
on	O
maintenance	O
dialysis	O
in	O
Rasoul	O
-	I:C0019994
e	I:C0019994
-	I:C0019994
Akram	I:C0019994
and	I:C0019994
Madaen	I:C0019994
Hospitals	I:C0019994
were	O
enrolled	O
in	O
this	O
randomized	O
clinical	I:C0206034
trial	I:C0206034
.	O

One	O
hundred	O
and	O
seventeen	O
end	O
-	I:C0022661
stage	I:C0022661
renal	I:C0022661
disease	I:C0022661
patients	O
who	O
were	O
on	O
maintenance	O
dialysis	B:C0011946
in	O
Rasoul	O
-	I:C0019994
e	I:C0019994
-	I:C0019994
Akram	I:C0019994
and	I:C0019994
Madaen	I:C0019994
Hospitals	I:C0019994
were	O
enrolled	O
in	O
this	O
randomized	O
clinical	I:C0206034
trial	I:C0206034
.	O

One	O
hundred	O
and	O
seventeen	O
end	O
-	I:C0022661
stage	I:C0022661
renal	I:C0022661
disease	I:C0022661
patients	O
who	O
were	O
on	O
maintenance	O
dialysis	O
in	O
Rasoul	B:C0019994
-	I:C0019994
e	I:C0019994
-	I:C0019994
Akram	I:C0019994
and	I:C0019994
Madaen	I:C0019994
Hospitals	I:C0019994
were	O
enrolled	O
in	O
this	O
randomized	O
clinical	I:C0206034
trial	I:C0206034
.	O

One	O
hundred	O
and	O
seventeen	O
end	O
-	I:C0022661
stage	I:C0022661
renal	I:C0022661
disease	I:C0022661
patients	O
who	O
were	O
on	O
maintenance	O
dialysis	O
in	O
Rasoul	O
-	I:C0019994
e	I:C0019994
-	I:C0019994
Akram	I:C0019994
and	I:C0019994
Madaen	I:C0019994
Hospitals	I:C0019994
were	O
enrolled	O
in	O
this	O
randomized	B:C0206034
clinical	I:C0206034
trial	I:C0206034
.	O

These	O
patients	O
were	O
divided	O
into	O
two	O
groups	O
randomly	O
using	O
block	B:C0034656
randomization	I:C0034656
method	I:C0034656
(	O
57	O
patients	O
as	O
the	O
case	O
group	O
receiving	O
omega	O
-	I:C0015689
3	I:C0015689
for	O
12	O
weeks	O
and	O
60	O
as	O
the	O
control	O
group	O
)	O
.	O

These	O
patients	O
were	O
divided	O
into	O
two	O
groups	O
randomly	O
using	O
block	O
randomization	I:C0034656
method	I:C0034656
(	O
57	O
patients	O
as	O
the	O
case	O
group	O
receiving	O
omega	B:C0015689
-	I:C0015689
3	I:C0015689
for	O
12	O
weeks	O
and	O
60	O
as	O
the	O
control	O
group	O
)	O
.	O

Blood	B:C0178913
sample	I:C0178913
was	O
taken	O
from	O
all	O
patients	O
for	O
measurement	O
of	I:C0428462
lipid	I:C0428462
profile	I:C0428462
,	O
serum	O
hemoglobin	I:C0518015
,	O
and	O
C	O
-	I:C0201657
reactive	I:C0201657
protein	I:C0201657
at	O
baseline	O
as	O
well	O
as	O
after	O
the	O
completion	O
of	O
interventions	O
(	O
after	O
12	O
weeks	O
)	O
.	O

Blood	O
sample	I:C0178913
was	O
taken	O
from	O
all	O
patients	O
for	O
measurement	B:C0428462
of	I:C0428462
lipid	I:C0428462
profile	I:C0428462
,	O
serum	O
hemoglobin	I:C0518015
,	O
and	O
C	O
-	I:C0201657
reactive	I:C0201657
protein	I:C0201657
at	O
baseline	O
as	O
well	O
as	O
after	O
the	O
completion	O
of	O
interventions	O
(	O
after	O
12	O
weeks	O
)	O
.	O

Blood	O
sample	I:C0178913
was	O
taken	O
from	O
all	O
patients	O
for	O
measurement	O
of	I:C0428462
lipid	I:C0428462
profile	I:C0428462
,	O
serum	B:C0518015
hemoglobin	I:C0518015
,	O
and	O
C	O
-	I:C0201657
reactive	I:C0201657
protein	I:C0201657
at	O
baseline	O
as	O
well	O
as	O
after	O
the	O
completion	O
of	O
interventions	O
(	O
after	O
12	O
weeks	O
)	O
.	O

Blood	O
sample	I:C0178913
was	O
taken	O
from	O
all	O
patients	O
for	O
measurement	O
of	I:C0428462
lipid	I:C0428462
profile	I:C0428462
,	O
serum	O
hemoglobin	I:C0518015
,	O
and	O
C	B:C0201657
-	I:C0201657
reactive	I:C0201657
protein	I:C0201657
at	O
baseline	O
as	O
well	O
as	O
after	O
the	O
completion	O
of	O
interventions	O
(	O
after	O
12	O
weeks	O
)	O
.	O

Blood	O
sample	I:C0178913
was	O
taken	O
from	O
all	O
patients	O
for	O
measurement	O
of	I:C0428462
lipid	I:C0428462
profile	I:C0428462
,	O
serum	O
hemoglobin	I:C0518015
,	O
and	O
C	O
-	I:C0201657
reactive	I:C0201657
protein	I:C0201657
at	O
baseline	O
as	O
well	O
as	O
after	O
the	O
completion	O
of	O
interventions	B:C0184661
(	O
after	O
12	O
weeks	O
)	O
.	O

The	O
average	O
change	O
in	O
the	O
value	O
of	O
HDL-	B:C0023822
C	I:C0023822
was	O
significantly	O
more	O
in	O
the	O
patients	O
who	O
received	O
omega	O
-	I:C0015689
3	I:C0015689
than	O
in	O
the	O
control	O
group	O
(	O
MD	O
,	O
-	O
7	O
mg/dL	O
;	O
95	O
%	O
CI	O
,	O
-	O
11	O
to	O
0	O
p	O
=	O
0.000	O
)	O
.	O

The	O
average	O
change	O
in	O
the	O
value	O
of	O
HDL-	O
C	I:C0023822
was	O
significantly	O
more	O
in	O
the	O
patients	O
who	O
received	O
omega	B:C0015689
-	I:C0015689
3	I:C0015689
than	O
in	O
the	O
control	O
group	O
(	O
MD	O
,	O
-	O
7	O
mg/dL	O
;	O
95	O
%	O
CI	O
,	O
-	O
11	O
to	O
0	O
p	O
=	O
0.000	O
)	O
.	O

The	O
average	O
change	O
in	O
the	O
value	O
of	O
HDL-	O
C	I:C0023822
was	O
significantly	O
more	O
in	O
the	O
patients	O
who	O
received	O
omega	O
-	I:C0015689
3	I:C0015689
than	O
in	O
the	O
control	O
group	O
(	O
MD	B:C1828170
,	O
-	O
7	O
mg/dL	O
;	O
95	O
%	O
CI	O
,	O
-	O
11	O
to	O
0	O
p	O
=	O
0.000	O
)	O
.	O

Also	O
,	O
the	O
reduction	B:C0441610
in	O
serum	O
creatinine	I:C0600061
level	I:C0600061
was	O
more	O
in	O
the	O
omega	O
-	I:C0015689
3	I:C0015689
group	O
than	O
in	O
the	O
control	O
group	O
(	O
MD	O
,	O
0.7	O
mg/dL	O
;	O
95	O
%	O
CI	O
,	O
-	O
0.4	O
to	O
2.1	O
p	O
=	O
0.023	O
)	O
.	O

Also	O
,	O
the	O
reduction	O
in	O
serum	B:C0600061
creatinine	I:C0600061
level	I:C0600061
was	O
more	O
in	O
the	O
omega	O
-	I:C0015689
3	I:C0015689
group	O
than	O
in	O
the	O
control	O
group	O
(	O
MD	O
,	O
0.7	O
mg/dL	O
;	O
95	O
%	O
CI	O
,	O
-	O
0.4	O
to	O
2.1	O
p	O
=	O
0.023	O
)	O
.	O

Also	O
,	O
the	O
reduction	O
in	O
serum	O
creatinine	I:C0600061
level	I:C0600061
was	O
more	O
in	O
the	O
omega	B:C0015689
-	I:C0015689
3	I:C0015689
group	O
than	O
in	O
the	O
control	O
group	O
(	O
MD	O
,	O
0.7	O
mg/dL	O
;	O
95	O
%	O
CI	O
,	O
-	O
0.4	O
to	O
2.1	O
p	O
=	O
0.023	O
)	O
.	O

Also	O
,	O
the	O
reduction	O
in	O
serum	O
creatinine	I:C0600061
level	I:C0600061
was	O
more	O
in	O
the	O
omega	O
-	I:C0015689
3	I:C0015689
group	O
than	O
in	O
the	O
control	O
group	O
(	O
MD	B:C1828170
,	O
0.7	O
mg/dL	O
;	O
95	O
%	O
CI	O
,	O
-	O
0.4	O
to	O
2.1	O
p	O
=	O
0.023	O
)	O
.	O

The	O
change	O
in	O
other	O
indices	B:C0918012
including	O
serum	O
triglyceride	I:C1287372
,	O
total	O
cholesterol	I:C0428466
,	O
and	O
serum	O
hemoglobin	I:C0019029
levels	I:C0019029
was	O
not	O
different	O
between	O
the	O
two	O
groups	O
.	O

The	O
change	O
in	O
other	O
indices	O
including	O
serum	B:C1287372
triglyceride	I:C1287372
,	O
total	O
cholesterol	I:C0428466
,	O
and	O
serum	O
hemoglobin	I:C0019029
levels	I:C0019029
was	O
not	O
different	O
between	O
the	O
two	O
groups	O
.	O

The	O
change	O
in	O
other	O
indices	O
including	O
serum	O
triglyceride	I:C1287372
,	O
total	B:C0428466
cholesterol	I:C0428466
,	O
and	O
serum	O
hemoglobin	I:C0019029
levels	I:C0019029
was	O
not	O
different	O
between	O
the	O
two	O
groups	O
.	O

The	O
change	O
in	O
other	O
indices	O
including	O
serum	O
triglyceride	I:C1287372
,	O
total	O
cholesterol	I:C0428466
,	O
and	O
serum	B:C0019029
hemoglobin	I:C0019029
levels	I:C0019029
was	O
not	O
different	O
between	O
the	O
two	O
groups	O
.	O

The	O
multivariable	B:C0034980
linear	I:C0034980
regression	I:C0034980
analysis	I:C0034980
showed	O
no	O
difference	O
in	O
serum	O
HDL	I:C0392885
level	I:C0392885
between	O
the	O
two	O
groups	O
adjusted	O
for	O
sex	O
,	O
age	O
,	O
and	O
time	O
of	O
dialysis	O
,	O
while	O
the	O
level	O
of	I:C0428472
serum	I:C0428472
HDL	I:C0428472
-	I:C0428472
C	I:C0428472
could	O
be	O
adversely	O
predicted	O
by	O
duration	O
time	O
.	O

The	O
multivariable	O
linear	I:C0034980
regression	I:C0034980
analysis	I:C0034980
showed	O
no	O
difference	O
in	O
serum	B:C0392885
HDL	I:C0392885
level	I:C0392885
between	O
the	O
two	O
groups	O
adjusted	O
for	O
sex	O
,	O
age	O
,	O
and	O
time	O
of	O
dialysis	O
,	O
while	O
the	O
level	O
of	I:C0428472
serum	I:C0428472
HDL	I:C0428472
-	I:C0428472
C	I:C0428472
could	O
be	O
adversely	O
predicted	O
by	O
duration	O
time	O
.	O

The	O
multivariable	O
linear	I:C0034980
regression	I:C0034980
analysis	I:C0034980
showed	O
no	O
difference	O
in	O
serum	O
HDL	I:C0392885
level	I:C0392885
between	O
the	O
two	O
groups	O
adjusted	O
for	O
sex	O
,	O
age	O
,	O
and	O
time	O
of	O
dialysis	B:C0011946
,	O
while	O
the	O
level	O
of	I:C0428472
serum	I:C0428472
HDL	I:C0428472
-	I:C0428472
C	I:C0428472
could	O
be	O
adversely	O
predicted	O
by	O
duration	O
time	O
.	O

The	O
multivariable	O
linear	I:C0034980
regression	I:C0034980
analysis	I:C0034980
showed	O
no	O
difference	O
in	O
serum	O
HDL	I:C0392885
level	I:C0392885
between	O
the	O
two	O
groups	O
adjusted	O
for	O
sex	O
,	O
age	O
,	O
and	O
time	O
of	O
dialysis	O
,	O
while	O
the	O
level	B:C0428472
of	I:C0428472
serum	I:C0428472
HDL	I:C0428472
-	I:C0428472
C	I:C0428472
could	O
be	O
adversely	O
predicted	O
by	O
duration	O
time	O
.	O

Similar	O
regression	B:C3161035
model	I:C3161035
showed	O
a	O
between	O
-	O
group	O
difference	O
in	O
serum	O
creatinine	I:C0600061
in	O
the	O
presence	O
of	O
potential	O
confounders	O
.	O

Similar	O
regression	O
model	I:C3161035
showed	O
a	O
between	O
-	O
group	O
difference	O
in	O
serum	B:C0600061
creatinine	I:C0600061
in	O
the	O
presence	O
of	O
potential	O
confounders	O
.	O

The	O
change	O
in	O
serum	B:C0392885
HDL	I:C0392885
level	I:C0392885
following	O
use	O
of	O
omega	O
-	I:C0015689
3	I:C0015689
supplement	O
is	O
influenced	O
by	O
time	O
of	O
dialysis	O
,	O
not	O
by	O
drug	O
effect	O
.	O

The	O
change	O
in	O
serum	O
HDL	I:C0392885
level	I:C0392885
following	O
use	O
of	O
omega	B:C0015689
-	I:C0015689
3	I:C0015689
supplement	O
is	O
influenced	O
by	O
time	O
of	O
dialysis	O
,	O
not	O
by	O
drug	O
effect	O
.	O

The	O
change	O
in	O
serum	O
HDL	I:C0392885
level	I:C0392885
following	O
use	O
of	O
omega	O
-	I:C0015689
3	I:C0015689
supplement	O
is	O
influenced	O
by	O
time	O
of	O
dialysis	B:C0011946
,	O
not	O
by	O
drug	O
effect	O
.	O

However	O
,	O
consumption	B:C1947907
of	O
omega	O
-	I:C0015689
3	I:C0015689
can	O
significantly	O
reduce	O
serum	O
creatinine	I:C0600061
.	O

However	O
,	O
consumption	O
of	O
omega	B:C0015689
-	I:C0015689
3	I:C0015689
can	O
significantly	O
reduce	O
serum	O
creatinine	I:C0600061
.	O

However	O
,	O
consumption	O
of	O
omega	O
-	I:C0015689
3	I:C0015689
can	O
significantly	O
reduce	O
serum	B:C0600061
creatinine	I:C0600061
.	O

